Effect of tenofovir disoproxil and telbivudine on the growth and development of infants by blocking mother-to-child transmission of hepatitis B virus

Abstract

Purpose: To investigate the effect of tenofovir disoproxil and telbivudine on the growth and development of infants after blocking mother-to-child transmission (MTCT) of hepatitis B virus (HBV).
 Methods: Seventy pregnant women with chronic hepatitis B (CHB) were recruited and allocated to tenofovir disoproxil group (n = 35) and telbivudine group (n = 35) using random number table method. Tenofovir disoproxil group was given 300 mg tenofovir disoproxil orally four times daily, while telbivudine group was given telbivudine 600 mg orally four times daily.
 Results: After treatment, both groups showed no significant differences in serum HBV-DNA and ALT levels before delivery and 3 months after delivery (p > 0.05). Both groups showed no remarkable differences in the incidence of hypohydramnios, cholestasis, hypothyroidism, anemia, prolonged labor, fetal distress, and placental adhesions (p > 0.05). Both groups showed no significant differences in the rates of premature rupture of membranes, preterm birth, vaginal delivery, and cesarean section (p > 0.05). Both groups showed no significant differences in neonatal sex, gestational age at birth, weight, length, and Apgar scores (p > 0.05). The differences in the positive rates of HBVsAg, HBsAb, and HBeAg at birth and at 12 months were not statistically noticeable (p > 0.05).
 Conclusion: Tenofovir disoproxil and telbivudine reduce HBV-DNA levels, effectively blocks MTCT, and have a similar safety profile for infants. Further investigations to confirm th

Preliminary study on the relationship between recurrence and quasispecies characteristics in P region of hepatitis B virus genome of chronic hepatitis B patients treated with lamivudine

“…However, there is limited research on whether complexity and changes of quasispecies influence HBV relapse after drug withdrawal and its related mechanism. This study aims to investigate quasispecies features of P region in HBV DNA among chronic HBV (CHB) patients receiving LAM therapy using cloning techniques [2]. The study also aims to determine the effects of these quasispecies on HBV relapse after drug withdrawal.…”